Cenduit LLC - IWRS
Cenduit LLC - IWRS is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia
Sponsor Arrowhead Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- Enrollment was restricted to participants who completed the 48-week treatment period in parent studies AROAPOC3-2001 or AROAPOC3-2002.
- Following a 22 November 2022 protocol amendment, participants receiving plozasiran 50 mg were changed to 25 mg every 3 months, and all active participants subsequently received 25 mg every 3 months for the remainder of the study.
- From 25 September 2024, participants could self-administer study drug using a prefilled syringe at the study site under investigator or designated-staff supervision.
These findings describe the trial, not the service provider’s performance or responsibility.
Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase II, single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION)
Sponsor Merck Healthcare KGaA
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Cenduit LLC - IWRS?
The 2026-10-09 snapshot links Cenduit LLC - IWRS to 3 distinct CTIS trials. Recorded services include Interactive response technology (IRT). These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Cenduit LLC - IWRS?
The most frequently recorded therapeutic areas are Metabolic Disorders. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Cenduit LLC - IWRS conducted?
The linked trials record locations in 8 countries, including Netherlands, Germany, Spain, France, Italy. These are trial locations, not confirmed office locations or countries where Cenduit LLC - IWRS delivered services.
What can this page tell me about Cenduit LLC - IWRS's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Cenduit LLC - IWRS. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Cenduit LLC - IWRS